Medicxi, Tai­ho in­fuse €30M in­to Evotec spin­out — eye­ing can­cer meds tar­get­ing DNA dam­age re­sponse path­ways

Bet­ting on DNA dam­age re­sponse as the next big fron­tier in can­cer ther­a­pies, Evotec is spin­ning out some of its dis­cov­ery-stage work and drug tar­gets in­to a start­up dubbed Break­point Ther­a­peu­tics.

Medicxi and Tai­ho Ven­tures are jump­ing on board for an ini­tial €30 mil­lion ($33.6 mil­lion) haul along­side the Ger­man biotech. For Medicxi the project aligns close­ly with its as­set-cen­tric in­vest­ing phi­los­o­phy, while Tai­ho will be draw­ing from an ex­pand­ed in­vest­ment pool that it has pre­vi­ous­ly in­di­cat­ed would be re­served for first-in-class on­col­o­gy pro­grams.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER